Media Contact

Osivelotor is an oral investigational drug for the treatment of sickle cell disease (SCD) designed to inhibit hemoglobin polymerization. In a phase 1, open-label ADME study conducted in healthy participants at ICON’s cli...

Visit us at DIA Philadelphia, 14–18 June, Booth \#1426, and explore ICON’s solutions spanning AI-driven trials, regulatory strategy, faster start-up and high-performing site models. https://ow.ly/1VF950Z29B7

We’re pleased to be part of ACRO’s Good Clinical Podcast focused on advancing rare disease research through AI innovation and patient trust. In the discussion, ICON’s Tanya Binette highlights where AI is delivering valu...

More than a decade ago, Yordan Zahariev joined ICON as a Clinical Trial Assistant. Today, he leads one of ICON's largest CTA teams in Bulgaria as a Clinical Operations Manager. In our latest career story, Yordan reflect...

Attending CTO East Coast in Boston? Join Padma Varadharajan on 30 June at 9:30am for her core session entitled: “Practical considerations for navigating the landscape of global oncology trials in 2026 and beyond.” This ...

ICON is a proud supporter of Global Fatty Liver Awareness Day, raising awareness and driving change for the millions of people worldwide living with steatotic (fatty) liver disease, their families, and carers. By 2030, a...

Steatotic (fatty) liver disease is a silent global epidemic, often underdiagnosed despite its growing impact. Beyond the liver, it is closely linked to obesity, type 2 diabetes andhyperlipidaemia, driving significant car...

We're proud to share that ICON has been named one of Forbes America's Best Employers for New Graduates 2026. The recognition is based on independent surveys of early-career professionals across the US, covering culture,...

We are excited to announce that Cytek Aurora 5L Spectral Flow Cytometers are now live in our bioanalytical labs in the Netherlands and US. With the new addition we are offering: 1) Development/transfer, validation, and ...

Site performance remains one of the most critical drivers of trial success. Through FIRECREST, ICON is enhancing site engagement, improving consistency and delivering stronger study execution at scale. Visit Booth \#1426...

Cut point determination is essential in ADA assay development, and while statistical methods like Tukey’s test can lead to ultra-low cut points (ULCPs), concerns around reliability and false positives may be overstated. ...

ICON is proud to sponsor the SOLAR conference. Our hepatology specialists will be on-site (25-27 June), talking with peers about the practical side of running liver disease trials from AI-driven site selection to imagi...